Browsing Tag
Nasdaq biotechnology
1 post
Kala Bio lands $6m lifeline as David E. Lazar takes control in turnaround bid
Find out how Kala Bio’s $6 million financing and leadership reset after the failed KPI-012 trial is shaping its survival strategy and investor outlook.